Defendant Name: Alexion Pharmaceuticals, Inc.

Defendant Type: Public Company

Document Reference: 2020-149

Document Details

Legal Case Name In the Matter of Alexion Pharmaceuticals, Inc.
Document Name SEC Charges Alexion Pharmaceuticals with FCPA Violations
Document Date 02-Jul-2020
Document Format Administrative Proceeding
File Number 3-19852
Allegation Type Foreign Corrupt Practices Act
Document Summary The SEC stated that: "Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA)."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Monetary Penalties:

Disgorgement

Individual:     $14,210,194.00 Shared:    

Civil Penalty

Individual:     $3,500,000.00 Shared:    

Pre-Judgment Interest

Individual:     $3,766,337.00 Shared:    

Related Documents:

34-89214 02-Jul-2020 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On July 2, 2020, the SEC instituted settled cease-and-desist proceedings against Alexion Pharmaceuticals, Inc. The SEC stated: "These proceedings arise out of Alexion's violations of the internal accounting controls and recordkeeping provisions of the Foreign Corrupt Practices Act of 1977."